What is the success rate of stem cell therapy for Primary Immunodeficiency?
There is no single HSCT or cell-therapy success rate across primary immunodeficiencies. Outcomes depend on diagnosis, genotype, age, infections and organ damage, donor match, conditioning and centre; review survival, immune reconstitution, graft failure, graft-versus-host disease and follow-up for the exact protocol.
What the evidence shows for Primary Immunodeficiency
Evidence and eligibility are diagnosis-, genotype-, donor- and centre-specific. HSCT may require conditioning and carries infection, graft failure, graft-versus-host disease and organ-toxicity risks; some disorders instead use immunoglobulin, antimicrobial, targeted immune or gene-based treatment. The NIAID GATA2-deficiency factsheet illustrates diagnosis-specific use of HSCT. It cannot validate a generic placental, stromal or exosome product.
Am I a candidate? → · Primary Immunodeficiency: full overview → · Primary Immunodeficiency cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.